Current Access to Anaplastic Lymphoma Kinase Testing and Targeted Therapies for Non–Small Cell Lung Cancer in Brazil: Results From a Cross-Sectional Survey (LACOG 1224-GBOT)
JCO Global Oncology · 2026-06 · 12 (6)
DOI: 10.1200/go-26-00117 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift JCO Global Oncology, 2026-06. Verfasst von Eldsamira Mascarenhas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Instituto D'Or de Ensino e Pesquisa, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase, Lung Neoplasms, Health Services Accessibility. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
PURPOSE In Brazil, diagnosing and treating non–small cell lung cancer (NSCLC) with actionable molecular alterations pose substantial challenges because of health care disparities. Anaplastic lymphoma kinase (ALK) rearrangements represent a clinically relevant subset with highly effective targeted therapies. However, real-world access to ALK diagnostics and treatments across different Brazilian health care sectors remains inadequately characterized. METHODS We conducted a cross-sectional survey of Brazilian oncologists between October 2024 and March 2025 to assess the availability of ALK testing and targeted therapies, alongside perceived implementation barriers. Of 197 responses collected, 156 were included in the final analytic cohort. Data were analyzed using descriptive statistics, and categorical variables were reported as proportions with 95% CIs. RESULTS Within the final analytic cohort (N = 156), 93.9% of the respondents practicing in the private sector (n = 147) reported access to ALK testing, whereas only 43.9% of those practicing in the public health care system (n = 107) had access. Access to ALK-targeted therapies was limited for the public health care population: 7.1% received crizotinib and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Instituto D'Or de Ensino e Pesquisa, Rio de Janeiro, Brazil.
- Grupo Brasileiro de Oncologia Torácica (GBOT), Porto Alegre, Brazil.
- Hospital São Lucas da PUCRS (HSL), Porto Alegre, Brazil.
- Oncoclínicas, Porto Alegre, Brazil.
- Hospital Alemão Oswaldo Cruz (HAOC), São Paulo, Brazil.
- Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
ORCID-Profile: Eldsamira Mascarenhas, Clarissa Baldotto, Ana Caroline Z Gelatti, Carlos Henrique A Teixeira, Taiane F Rebelatto, Caio de A Monteiro, Rafaela G de Jesus, Vladmir C Cordeiro de Lima
Zitieren
APA
Mascarenhas, E., Baldotto, C., Gelatti, A. C. Z., Teixeira, C. H. A., Rebelatto, T. F., Monteiro, C. A., de Jesus, R. G., & Cordeiro de Lima, V. C. (2026). Current Access to Anaplastic Lymphoma Kinase Testing and Targeted Therapies for Non–Small Cell Lung Cancer in Brazil: Results From a Cross-Sectional Survey (LACOG 1224-GBOT). JCO Global Oncology, 12(6). https://doi.org/10.1200/go-26-00117
Vancouver
Mascarenhas E, Baldotto C, Gelatti ACZ, Teixeira CHA, Rebelatto TF, Monteiro CA, et al. Current Access to Anaplastic Lymphoma Kinase Testing and Targeted Therapies for Non–Small Cell Lung Cancer in Brazil: Results From a Cross-Sectional Survey (LACOG 1224-GBOT). JCO Global Oncology. 2026;12(6). doi:10.1200/go-26-00117
BibTeX
@article{Mascarenhas2026,
author = {Mascarenhas, Eldsamira and Baldotto, Clarissa and Gelatti, Ana Caroline Z and Teixeira, Carlos Henrique A and Rebelatto, Taiane F and Monteiro, Caio de A and de Jesus, Rafaela G and Cordeiro de Lima, Vladmir C},
title = {Current Access to Anaplastic Lymphoma Kinase Testing and Targeted Therapies for Non–Small Cell Lung Cancer in Brazil: Results From a Cross-Sectional Survey (LACOG 1224-GBOT)},
journal = {JCO Global Oncology},
year = {2026},
volume = {12},
number = {6},
doi = {10.1200/go-26-00117}
}
EUVIMED